Evaluation of Esflurbiprofen Topical System Bioavailability and Adhesion Compared to Oral Flurbiprofen in a Phase I Crossover Study in Healthy Volunteers

The primary objective of this study is to evaluate the **bioavailability** of the active substance in the newly developed Esflurbiprofen Topical System (EFTS) compared to a marketed oral flurbiprofen-containing tablet formulation. This assessment is conducted after multiple dose administration in healthy subjects. The study also includes an evaluation of the **adhesion** of the EFTS patch. Understanding the bioavailability and adhesion characteristics of the EFTS is clinically relevant as it may inform the potential for alternative delivery methods of flurbiprofen, which could impact patient compliance and therapeutic outcomes.

The clinical trial involves a study population of **healthy volunteers** participating in a **bioavailability and patch adhesion trial**. The trial includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study. The therapeutic indication is not being studied in this trial, and no specific principal inclusion criteria have been outlined. The sponsor has not provided further information regarding the general health status of the participants.

The clinical trial is designed as a **phase I**, open-label, randomized, two-period, cross-over study aimed at evaluating the **bioavailability** and adhesion of a newly developed Esflurbiprofen Topical System (EFTS) patch compared to a marketed oral flurbiprofen-containing tablet formulation. The study will be conducted in healthy subjects, with no therapeutic indication being studied. The trial is expected to commence recruitment on January 2, 2025, and conclude by April 30, 2025. Participants will be involved in the study for a duration that includes multiple dosing periods, with the exact length of involvement dependent on the specific protocol of the cross-over design.

The sequence of study visits will begin with an inclusion (screening) visit, where eligibility criteria will be assessed to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will enter the first treatment period, during which they will receive either the EFTS patch or the oral tablet. After a washout period, participants will cross over to the alternate treatment in the second period. Follow-up visits will be scheduled to monitor the participants' health and gather data on the primary and secondary endpoints, which include the assessment of the patch's adhesion and the systemic availability of the active substance. The end-of-study visit will occur after the completion of both treatment periods and will involve final assessments and data collection.

Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to adhere to the study protocol, or withdraw consent. The study's design ensures that all procedures are conducted in a controlled environment, with adherence to ethical standards and regulatory requirements. The trial's methodology and design are structured to provide robust data on the comparative bioavailability and adhesion properties of the EFTS patch, contributing valuable insights into its potential application in clinical settings.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on January 2, 2025, with an estimated completion date of April 30, 2025. The efficacy of the investigational treatment will be evaluated using specific parameters, although these parameters are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data. The study will adhere to rigorous standards typical of Phase 3 trials, ensuring that the results are reliable and can contribute to the understanding of the treatment's effectiveness. The trial's design and execution will be aligned with clinical and regulatory expectations for Phase 3 studies, focusing on generating robust efficacy data.